HealthEquity Inc. shares fell sharply in pre-market trading, declining 7.6% after the company posted second-quarter fiscal 2027 results before markets opened. The quarterly report produced results that tracked closely with analyst expectations but stopped short of delivering the upside many investors appeared to have priced into the stock.
On the top line, revenue increased 8% year-over-year to $350.7 million. On a per-share basis, non-GAAP net income per diluted share rose 15% to $1.24. Those figures were essentially in line with the consensus estimates of $349.22 million in revenue and $1.19 in EPS, offering little in the way of an earnings surprise.
Operational highlights and capital return
Management underscored a number of record operational metrics for the quarter. The company reported a record Adjusted EBITDA margin of 48%, a record number of HSA accounts at 10.7 million and record HSA assets approaching $38 billion. In addition, HealthEquity returned $108.1 million to shareholders through share repurchases during the quarter. Management also raised the companys fiscal 2027 guidance.
Despite these positive data points, the sequential picture for earnings showed a plateau: non-GAAP EPS was unchanged from the first quarter of fiscal 2027, when it also stood at $1.24. That lack of sequential growth, combined with guidance that may not have meaningfully exceeded already-elevated market expectations, appears to have been a key factor behind the pre-market selling.
Market context
The weakness in HealthEquity shares was company-specific rather than broad-based. Major equity benchmarks were positive at the time of the move, with the NASDAQ up 0.8% and the S&P 500 up 0.3%. The prior trading session had seen upward pressure on Treasury yields following hotter-than-anticipated annual PCE figures - headline PCE growth of 3.7% and core PCE of 3.3% - a macro backdrop that can weigh on growth-oriented healthcare names that trade at premium multiples.
Analyst sentiment heading into the print reflected generally bullish expectations: the average 12-month analyst price target for HealthEquity was $118.53, and 15 analysts had the stock rated a buy, with no sell ratings reported. The stock had rallied over the prior year and was trading near its 52-week high of $107.62 before the quarterly disclosure, suggesting that much of the anticipated positive news may already have been priced into the shares.
Takeaway
Investors interpreted the quarter as an example of a "buy the rumor, sell the news" dynamic. While HealthEquity again demonstrated durable growth in HSA accounts and custodial assets, the modest margin by which results exceeded or simply matched expectations, together with a persistent inflation backdrop, was sufficient to spark a sizable pre-open decline.
Looking ahead, the company has lifted its fiscal 2027 guidance, but the market reaction suggests investors will be closely watching subsequent quarters for proof of renewed sequential earnings momentum beyond the record operational metrics reported in Q2.